



ISSN: 2578-3335 (Print) 2578-3343 (Online)

Volume 4 | Issue 1

Article 1

2022

Thyrotoxic Periodic Paralysis: A Case Report and Discussion of Clinical and Imaging Features

Kristian Quevada

Cooper Medical School of Rowan University, quevad76@rowan.edu

Kishan Patel

Cooper University Hospital, patel-kishan1@cooperhealth.edu

Pauline Germaine

Cooper University Hospital, germaine-pauline@CooperHealth.edu

Cooper Rowan Medical Journal: <https://rdw.rowan.edu/crjcsm>

Would you like to be a reviewer? Please fill in this [short form](#) to express your interest.

Recommended Citation

Quevada, Kristian; Patel, Kishan; and Germaine, Pauline (2022) "Thyrotoxic Periodic Paralysis: A Case Report and Discussion of Clinical and Imaging Features," *Cooper Rowan Medical Journal*: Vol. 4: Iss. 1, Article 1.

DOI: 10.31986issn.2578.3343_vol4iss1.1

Available at: <https://rdw.rowan.edu/crjcsm/vol4/iss1/1>



This work is licensed under a [Creative Commons Attribution 4.0 License](#).

This Case Reports and Case Series is brought to you for free and open access by the Rowan University Journals at Rowan Digital Works. It has been accepted for inclusion in Cooper Rowan Medical Journal by an authorized editor of Rowan Digital Works. For more information, please contact brush@rowan.edu.

Thyrotoxic Periodic Paralysis: A Case Report and Discussion of Clinical and Imaging Features

Thyrotoxic Periodic Paralysis: A Case Report and Discussion of Clinical and Imaging Features

Kristian Quevada (B.E.), M.D. Candidate^{1*}, Kishan Patel, DO² & Pauline Germaine, DO^{2,1}

¹Cooper Medical School of Rowan University, Camden, NJ

²Department of Radiology, Cooper University Healthcare, Camden, NJ

*Corresponding author: quevad76@rowan.edu (Kristian Quevada (B.E.), M.D. Candidate)

ABSTRACT

Thyrotoxic Periodic Paralysis (TPP) is a rare manifestation of thyrotoxicosis, resulting in periodic episodes of acute onset muscle weakness in the setting of hypokalemia. The thyrotoxic form of Hypokalemic Periodic Paralysis (HPP) is less studied than the more well-known familial form due to fewer reported cases and smaller prevalence. This case study presents a 30-year-old African American male with multiple episodes of acute lower extremity muscle weakness, tachycardia, and a history of heat intolerance. Abnormal findings on thyroid ultrasound coupled with increased thyroid related immunoglobulins led to a diagnosis of TPP related to exacerbation of newly-found Graves' disease. The case study will further discuss the importance of imaging in assessing the etiology of TPP with review of relevant literature.

Keywords: thyrotoxic periodic paralysis, thyrotoxicosis, hypokalemia, hypokalemic periodic paralysis, Graves' disease

INTRODUCTION

Thyrotoxic Periodic Paralysis (TPP) is a rare manifestation of thyrotoxicosis. It is one of the lesser common subsets of hypokalemic periodic paralysis (HPP), the more common subset being Familial Hypokalemic Periodic Paralysis (FHPP). HPP can be extremely dangerous for patients to develop, since episodes may potentially lead to fatal muscle weakness via involvement of respiratory muscles, or life-threatening cardiac arrhythmias in the setting of hypokalemia¹. The prevalence of TPP in North America is stated to be 0.1-0.2%². Majority of the cases are found in the Asian population, and are extremely rare in the African American patients. Thus, there is significant value in studying individual cases of TPP in the African American population, as there is sparse data on such a rare occurrence of an

already rare disease.

1. Potassium 1.6 (L) (3.5-5.0 mmol/L)
2. Phosphate 0.6 (L) (2.7-4.6 mg/d)
3. Magnesium 1.5 (L) (1.6-2.6 mg/dL)
4. TSH <0.01 (L) (0.27-4.20 u[IU]/mL)
5. Free T4 3.3 (H) (0.8-1.8 ng/dL)
6. Free T3 8.9 (H) (2.0-4.4 pg/mL)

THYROID STIMULATING IMMUNOGLOBULIN 409 (H (<140% [BASELINE])

Due to abnormalities of the thyroid panel, thyroid ultrasound was requested. A diffusely heterogeneous and enlarged thyroid gland was visualized on grayscale ultrasound, with markedly increased vascularity on color Doppler assessment.

DISCUSSION

Clinical Presentation:

TPP is a rare condition presenting with periodic episodes of muscle weakness in the setting of hypokalemia and hyperthyroidism. The muscle weakness usually starts in the lower extremities and the laboratory values show elevated free triiodothyronine or thyroxine levels. TPP can also present with nonspecific cramping, muscle pain, stiffness, and decreased deep tendon reflexes, with intermittent resolution of symptoms³. Concurrent symptoms of hyperthyroidism, such as palpitations, weight loss, tremor, and heat intolerance, may also be present⁴. Episodes may be precipitated by meals with high carbohydrates, alcohol, trauma, and stress^{3,5}. Our patient's presentation aligns with the typical presentation of TPP described above, demonstrating periodic episodes of weakness (acute myopathy) in the lower extremities, signs of hyperthyroidism, and elevated free T3 and T4, all within the setting of hypokalemia. Ultrasound imaging confirmed clinical findings of hyperthyroidism via thyroid storm, noting enlarged heterogeneous thyroid gland with diffusely increased vascularity on color Doppler assessment. Graves' disease workup confirmed autoimmune activity behind hyperthyroidism.

Demographics:

TPP typically presents in Asian males around the 2nd to 5th decades and has a prevalence of 10% in Asian countries. The prevalence of TPP is about 0.1-0.2% in non-Asian populations^{5,6}. In Japanese people, the

DRw8 subtype of the HLA gene complex increases their risk of developing periodic paralysis⁷. However, the same subtype found in the Caucasian population increases their risk for Graves' disease, but not necessarily periodic paralysis⁸. TPP seems to be primarily studied in Asian populations, but not so much in the Caucasian or African American patients⁹. The first couple cases of an African American patient presenting with TPP in literature were published in 1961 and 1984, the latter of which did not possess the above HLA subtype^{10,11}. A report in 1994 describes that 4 cases have been reported within a 13 year period at the researchers' institution, implying that cases of TPP in the African American population may be underreported¹². Since then, more cases of TPP in the African American population have been described, reporting similarly to the clinical presentation of TPP described above¹³⁻¹⁸, with an additional case being reported from native Africa as well¹⁹.

Differential Diagnoses:

FHPP and Myasthenic Syndromes constitute other potential muscular disorders that must be ruled out. FHPP is an autosomal dominant genetic disorder characteristic of mutations in ion channels of the skeletal muscle sarcolemma (such as the alpha1 subunit of the dihydropyridine-sensitive calcium channel and sodium channel SCN4A)²⁰. FHPP age of onset is typically around the first two decades and frequency of attacks diminishes with age, meaning FHPP is likely to present at a younger age than TPP²¹. Myasthenic Syndromes, such as myasthenia gravis and Lambert Eaton myasthenic syndrome, are autoimmune disorders that affect the neuromuscular junction causing progressive muscle weakness in various muscle groups such as proximal limbs²². Myasthenia gravis is becoming increasingly common in the elderly, men being more likely to be diagnosed after the age of 50, and Lambert Eaton myasthenic syndrome usually presents over 40 years of age^{22,23}. Both of these myasthenic syndromes tend to present later in life than TPP.

Pathophysiology:

The pathophysiology behind TPP still remains unclear. The Na⁺/K⁺-ATPase pump is responsible for maintaining the transmembrane difference of potassium in cells. Both insulin and beta-adrenergic catecholamines are known to activate the function of the Na⁺/K⁺-ATPase pump²⁴. Hyperthyroidism causes an increase in beta-adrenergic activity, which may activate the pump, driving potassium into cells and causing hypokalemia in the blood²⁵. Thyroid hormones may also have direct activity on Na⁺/K⁺-ATPase pumps, which may increase activity and function of these pumps²⁶. Having meals high in carbohydrates may also precipitate episodes of TPP due to an increase in insulin which activates Na⁺/K⁺-ATPase pumps²⁷.

Imaging Features:

Ultrasound is the primary imaging modality used in assessing the thyroid. In a retrospective study with

patients diagnosed with TPP, the most common finding on ultrasound consisted of an enlarged thyroid gland, as demonstrated in our patient. This study consisted of 13 patients that had undergone sonographic imaging. Another sonographic finding in the majority of the patients was hyperechoic regions and decreased echogenicity of the thyroid. In the group of patients with decreased echogenicity, the patients' thyroids were either diffusely hypoechoic or had multiple areas of hypoechogenicity. The imaging features closely resemble Graves' disease, which the majority of the patients were already diagnosed with²⁸. The thyroid will also be hyperemic on Doppler ultrasound²⁹, as was seen in our presented case. The imaging appearance of TPP can vary depending on if there is an underlying hyperthyroid disease. For example, in a recent case study, a male patient with no relevant past medical history was diagnosed with TPP. A thyroid ultrasound of this patient showed multiple bilateral thyroid nodules³⁰. TPP can be seen in various etiologies of hyperthyroidism, which can make its sonographic appearance quite variable at times.

Treatment:

Treatment in the setting of an acute attack includes general supportive care, potassium repletion, and nonselective beta blockade in the case of tachycardia or palpitations³. The patient should be monitored for rebound hyperkalemia after resolution of an acute attack. Treatment regimen should also work towards achieving a euthyroid state with options including antithyroid medications, radioactive iodine, or thyroidectomy in a patient with Graves' disease³. Definitive treatment of hyperthyroidism is noted to result in complete resolution of paralysis¹³. In the present case, the patient is prescribed propranolol and methimazole for prevention of further hyperthyroid attacks. The patient is currently doing well and follows up with endocrinology in the outpatient setting for management of his Graves' disease.

CONCLUSION

TPP is a rare manifestation of thyrotoxicosis that can be diagnosed through investigation of history of present illness, physical examination, laboratory values, and imaging. A history of multiple episodes of muscle weakness and concurrent tachycardia under a setting of hypokalemia and hyperthyroidism should raise a healthcare provider's index of suspicion for TPP. The use of grayscale ultrasound with color doppler can further confirm the etiology behind the hyperthyroidism, which may further support the diagnosis of TPP. Repletion of low potassium is shown to resolve an acute episode of TPP, and prevention of further hyperthyroid attacks via pharmacotherapy (such as propranolol and methimazole), radioactive iodine, or thyroidectomy can result in prevention of future episodes of paralysis secondary to TPP.



Figure 1 Transverse grayscale image of the thyroid gland at the level of the isthmus demonstrates diffuse enlargement and parenchymal heterogeneity of the entire gland, with overall increased echogenicity.




Figure 2




Figure 3 Transverse color (A) and power (B) doppler images of the thyroid gland at the level of the isthmus demonstrate diffusely increased vascularity.

REFERENCES

1. Alkaabi Juma M. Hypokalemic periodic paralysis: a case series, review of the literature and update of management. *European Journal of emergency medicine*. 2010;17:45-47.
2. Paul B, Hirudayaraj P, Baig M W. Thyrotoxic periodic paralysis: an unusual presentation of weakness. *Emergency Medicine Journal*. 2003;20:7-7.
3. Services EBSCO Information. *Dynamed*. 2021.
4. Salih Mahdi. Thyrotoxic periodic paralysis: an unusual presentation of hyperthyroidism. *Neth JMed*. 2017;75:315-335.
5. Rhee Eugene P, James A, Scott Anand S, Dighe . Case 4-2012: a 37-year-old man with muscle pain, weakness, and weight loss. *New England Journal of Medicine*. 2012;366:553-560.
6. Hassen Seife, Sara . Recurrent thyrotoxic periodic paralysis with normokalemia in a 36-year-old man: A case report. *Clinical Case Reports*. 2021;9:4849-4849.
7. Dixon A N, Jones R. Thyrotoxic periodic paralysis in a white woman. *Postgraduate medical journal*. 2002;78:687-688.
8. Sinharay R. Thyrotoxic periodic paralysis in western countries. *Postgraduate medical journal*. 2003;79:426-426.
9. Hsieh Chang-Hsun. Thyrotoxic periodic paralysis: an overview. *Annals of Saudi medicine*. 2004;24:418-422.
10. Jackman Roger L, Jones Robert E. Hyperthyroidism and periodic paralysis. *Archives of internal medicine*. 1964;113:657-664.
11. Kelly T M, Fishman Lawrence M. Thyrotoxic periodic paralysis in a black male. *Journal of endocrinological investigation*. 1984;7:517-519.
12. Kilpatrick Robin E, Seiler-Smith Susan, Levine Steven N. Thyrotoxic Hypokalemic Periodic Paralysis: Report of Four Cases in Black American Males1. *Thyroid*. 1994;4:441-445.
13. Munir , Irsa . Thyrotoxic periodic paralysis with sensory deficits in young African American male: a case report and literature review. *American journal of medical case reports*. 2019;7:138-138.

14. Glass Joshua, Osipoff Jennifer. Thyrotoxic periodic paralysis presenting in an African-American teenage male: case report. *International journal of pediatric endocrinology*. 2020;2020:1-4.
15. Godfrey Sean. SUN-519 Hypokalemic Periodic Paralysis. *Journal of the Endocrine Society*. 2020;4:519-519.
16. Sow , Maïmouna . Thyrotoxic hypokalemic periodic paralysis in two African black women. *The Pan African Medical Journal*. 2020;37:207-207.
17. Banerjee Ela. Skin Deep: A Rare Case of Thyrotoxic Periodic Paralysis in an African American Patient. *Journal of the Endocrine Society*. 2021;5:954-954.
18. Ngonyani Martin, Manji Hussein. Thyrotoxicosis: an unusual cause of periodic paralysis (a case report from Tanzania). *PAMJ-Clinical Medicine*. 2021;7:24-24.
19. Garla Vishnu, Vardhan . Thyrotoxic periodic paralysis: case report and review of the literature. *Electronic physician*. 2018;10:7174-7174.
20. Venance Shannon L. The primary periodic paralyses: diagnosis, pathogenesis and treatment. *Brain*. 2006;129(1):8-17.
21. Nicolle Michael W. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. *Continuum: Lifelong Learning in Neurology*. 2016;22:1978-2005.
22. Cannon Stephen C. An expanding view for the molecular basis of familial periodic paralysis. *Neuromuscular Disorders*. 2002;12:533-543.
23. Mareska Michael, Gutmann Laurie. Lambert-Eaton myasthenic syndrome. *Seminars in neurology*. 2004;24(02).
24. Pirkmajer Sergej, Chibalin Alexander V. Na, K-ATPase regulation in skeletal muscle. *American Journal of Physiology-Endocrinology and Metabolism*. 2016;311:1-31.
25. Levey Gerald S, Klein Irwin. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. *The American journal of medicine*. 1990;88:642-646.
26. Ginsberg Ann M. Triiodothyronine-induced thyrotoxicosis increases mononuclear leukocyte β -adrenergic receptor density in man. *The Journal of clinical investigation*. 1981;67:1785-1791.
27. Lee Kok, Onn . Hyperinsulinaemia in thyrotoxic hypokalaemic periodic paralysis. *The Lancet*. 1991;337:1063-1064.

28. King Ann D. Thyrotoxic periodic paralysis: sonographic appearances of the thyroid. *Journal of clinical ultrasound*. 2002;30:544-547.
29. Batch Jennifer T, Muhammad U, Jahngir Ismael, Rodriguez . Thyrotoxic Periodic Paralysis: An Incidental Diagnosis!. *Cureus*. 2020;12.
30. Tu Mei-Lan. An atypical presentation of high potassium renal secretion rate in a patient with thyrotoxic periodic paralysis: a case report. *BMC nephrology*. 2018;19:1-5.